In Brief: Cygnus/Yamanouchi
This article was originally published in The Gray Sheet
Executive Summary
Cygnus/Yamanouchi: Sign marketing and distribution agreement under which Tokyo-based Yamanouchi Pharmaceutical gains exclusive rights to sell the GlucoWatch continuous glucose monitoring device in Japan and Korea. According to terms of the deal, Redwood City, California-based Cygnus will have "primary responsibility" for completing product development and for manufacturing. Cygnus could receive up to $10 mil. in up-front and milestone payments under the deal; the agreement also includes royalties. In a pact announced in February, Cygnus licensed GlucoWatch to Becton Dickinson for all markets except Japan and Korea ("The Gray Sheet" Feb. 19, I&W-9)...
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.